Abstract
The c.40_42delAGA variant in the phospholamban gene (PLN) has been associated with dilated and arrhythmogenic cardiomyopathy, with up to 70% of carriers experiencing a major cardiac event by age 70. However, other carriers remain asymptomatic or show only mild symptoms in old age. To understand the mechanisms behind this incomplete penetrance, we evaluated potential phenotypic and genetic modifiers in 74 PLN c.40_42delAGA carriers identified in 36,339 participants of the Lifelines population cohort. Asymptomatic carriers (N=48) showed shorter QRS duration (-5.73 ms, p-value=0.001) compared to asymptomatic non-carriers and symptomatic carriers (N=26), and we replicated this in different subset of 21,771 participants from the Lifelines cohort (-3.87 ms, p-value=0.028) and in 592 carriers from the Arrhythmogenic Cardiomyopathy (ACM) PLN patient registry (-6.91 ms, p-value=0.0002). Furthermore, symptomatic carriers showed a higher correlation between genetic predisposition to higher QRS duration (PGSQRS) and QRS (p-value=1.98×10-8), suggesting that symptomatic PLN c.40_42delAGA carriers may have an increased sensitivity to the effect of genetic variation in cardiac rhythm. Our results may help improve risk prediction models for cardiac outcomes for future studies, while our approach could guide studies on genetic diseases with incomplete penetrance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Lifelines Biobank initiative has been made possible by funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG the Netherlands), University of Groningen and the Northern Provinces of the Netherlands (Drenthe, Friesland and Groningen). The generation and management of GWAS genotype data for the Lifelines Cohort Study is supported by the UMCG Genetics Lifelines Initiative (UGLI). UGLI is partly supported by a Spinoza Grant from NWO, awarded to Cisca Wijmenga. This study was supported by UMCG HAP grant CD017.0031/ronde 2017-2/nr324 (P.vdZ), by NWO VIDI grant number 917.164.455 (M.A.S), ERC advanced grant ERC-671274 (C.W.), by the NWO gravitation grant The Netherlands Organ-on-Chip Initiative 024.003.001 (C.W.) and Spinoza award NWOSPI 92-266 (C.W.); and by Colciencias fellowship ed.783 (E.A.L.M.), by Netherlands Heart Foundation (2017-21; 2017-11; 2018-30; 2020B005) (R.A.d.B. & R.d.B); and by the European Research Council (ERC CoG 818715) (R.A.d.B. & R.d.B); and Foundation leDucq (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN) (R.A.d.B. & R.d.B).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the medical ethical committee from the University Medical Center Groningen
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# jointly supervised this work.
We updated the list of the Netherlands ACM/PLN Registry Collaborators
Data Availability
All data produced in the present work are contained in the manuscript and supplementary information, and all date used to produce the results are available upon reasonable request